Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration

Cancer Res. 1990 Feb 1;50(3):606-14.

Abstract

A Phase I study of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) was undertaken in 21 patients with advanced malignancy or neutropenia. rhGM-CSF was administered once daily by i.v. bolus injection (0.3 to 3 micrograms/kg/day) or 2-h i.v. infusion (3 to 20 micrograms/kg day) for 10 days. rhGM-CSF at all i.v. doses caused an immediate transient decrease in circulating neutrophils, eosinophils, and monocytes. By 6 h after rhGM-CSF, circulating leukocyte levels were restored. Daily i.v. bolus dosing (0.3 to 3 micrograms/kg/day) did not elevate leukocyte levels except in one neutropenic patient. Daily 2-h i.v. infusions (10 to 20 micrograms/kg/day) caused a dose-dependent leukocytosis with increased levels of neutrophils (up to 4.3-fold), eosinophils (up to 18-fold), and monocytes (up to 3.5-fold). Marrow aspirates showed increased proportions of promyelocytes and myelocytes during rhGM-CSF administration. Retreatment after 10 days without rhGM-CSF resulted in a more marked leukocytosis at doses greater than or equal to 10 micrograms/kg/day. Platelet levels decreased for the first 3 days and then increased during the first course of rhGM-CSF administration. Two patients with chronic lymphocytic leukemia had a transient reduction in lymphocytosis. Serum cholesterol and albumin levels decreased, and vitamin B12 levels increased during rhGM-CSF treatment. At doses of up to 15 micrograms/kg/day, rhGM-CSF was relatively well tolerated by the patients, but adverse effects included bone pain, lethargy, fever, rash, and weight gain. A first dose reaction characterized by hypoxia and hypotension was identified at dose levels greater than or equal to 1 microgram/kg. Dosing i.v. was less potent at inducing a leukocytosis than previously observed for equivalent s.c. doses and was associated with a higher incidence of generalized rash and first dose reactions. The maximal tolerated dose of i.v. rhGM-CSF was 15 micrograms/kg/day. Phase II studies in which the derived effect is to raise leukocyte levels should be undertaken at rhGM-CSF doses of 3 to 15 micrograms/kg/day.

MeSH terms

  • Adult
  • Aged
  • Basophils
  • Colony-Stimulating Factors / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Eosinophils
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Growth Substances / administration & dosage*
  • Hematopoiesis / drug effects
  • Humans
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Leukocyte Count / drug effects
  • Lipids / blood
  • Lymphocytes
  • Middle Aged
  • Monocytes
  • Neoplasms / therapy*
  • Neutrophils
  • Platelet Count / drug effects
  • Recombinant Proteins
  • Serum Albumin / metabolism
  • Time Factors

Substances

  • Colony-Stimulating Factors
  • Growth Substances
  • Lipids
  • Recombinant Proteins
  • Serum Albumin
  • Granulocyte-Macrophage Colony-Stimulating Factor